“Long acting octreotide should be discontinued 4 to 6 weeks prior to imaging and the patient should be transitioned to a short acting regimen. The Octreotide and MIBG imaging often left referring physicians with unanswered questions while having the patient undergo multiple days of imaging and uncomfortable prep.įor example, here is the description of patient preparation a review published in the International Journal of Endocrinology Oncology: Until recently, providers relied heavily on the results of Octreotide (or Octreoscan) and MIBG scans for treatment guidance for somatostatin receptor-positive neuroendocrine tumors (NETs). The uptake of 68Ga-Dotatate reflects the level of somatostatin receptor density in neuroendocrine tumors. 68Ga-Dotatate, a positron-emitting analog of somatostatin, works by binding to such receptors. Neuroendocrine tumors have receptors for somatostatin, a hormone that regulates the endocrine system. The tumors develop in the hormone-producing cells of the body’s neuroendocrine system, and are located in organs such as the stomach, intestines, pancreas, and lungs. Neuroendocrine tumors are malignant and benign tumors that affect an estimated 47,300 individuals in Europe and the United States each year. Here, we aim to answer a few key questions about NETSPOT and how it is used: Background on NETSPOT The commercial product is a single dose kit for the preparation of a 68Ga-Dotatate injection manufactured by Advanced Accelerator Applications of Saint Genis-Pouilly, France.įor PET imaging facilities who may be more used to using Octreotide or Octreoscan, NETSPOT may prove to be a good alternative.
NETSPOT ( 68Ga-Dotatate) is a radioactive diagnostic agent used for PET imaging that is gaining ground among practices.įDA-approved in 2016, NETSPOT is used in imaging to locate somatostatin receptor positive neuroendocrine tumors in adult and pediatric patients.
0 kommentar(er)
